Cite

HARVARD Citation

    Desai, A. et al. (2022). Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease. Cancer. 128 (15), pp. 2967-2977. [Online]. 
  
Back to record